Drug metabolism in hepatosplenic schistosomiasis in the Sudan: a study with antipyrine.
Open Access
- 31 August 1978
- Vol. 19 (9) , 808-811
- https://doi.org/10.1136/gut.19.9.808
Abstract
The disposition of antipyrine following oral administration of 1200 mg has been investigated in 10 patients with histologically confirmed hepatosplenic schistosomiasis and 11 normal subjects living in Sudan. Drug metabolising activity as assessed by antipyrine clearance was similar in patients when compared with normal controls. We conclude that antipyrine disposition is normal in patients with clinically compensated hepatosplenic schistosomiasis.This publication has 15 references indexed in Scilit:
- MUTAGENIC ACTIVITIES INVITRO AND INVIVO OF 5 ANTISCHISTOSOMAL COMPOUNDS1977
- Infection with Schistosoma mansoni in the Gezire area of the Sudan.1976
- EFFECT OF SCHISTOSOMA-MANSONI INFECTION ON HEPATIC DRUG-METABOLIZING CAPACITY OF MICE1976
- A physiological approach to hepatic drug clearanceClinical Pharmacology & Therapeutics, 1975
- CLINICAL ASPECTS OF HEPATOSPLENIC SCHISTOSOMIASIS - CONTRAST WITH CIRRHOSIS1975
- Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administrationClinical Pharmacology & Therapeutics, 1974
- Clearance of Antipyrine‐Dependence of Quantitative Liver FunctionEuropean Journal of Clinical Investigation, 1974
- Determinants of serum antipyrine half-lives in patients with liver diseaseGut, 1973
- METABOLISM OF NIRIDAZOLE IN VARIOUS SPECIES, INCLUDING MANAnnals of the New York Academy of Sciences, 1969
- A New, Active Metabolite of ‘Miracil D’Nature, 1965